Natasha de Hosse
Acute Care · Vincennes, INNPI 1932390739
Payments from drug & device makers
Across 87 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$212
- Boehringer Ingelheim$167
- Amgen$165
- Actelion Pharmaceuticals US, Inc.$123
- Mylan Specialty L.p.$86
- Novo Nordisk$74
- plus $528 from 19 others
What the payments were for
- Food & beverage$1,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $212 |
| Boehringer Ingelheim | 11 | $167 |
| Amgen | 13 | $165 |
| Actelion Pharmaceuticals US, Inc. | 7 | $123 |
| Mylan Specialty L.p. | 6 | $86 |
| Novo Nordisk | 4 | $74 |
| GSK | 4 | $57 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $53 |
| Sanofi | 3 | $49 |
| Bayer | 3 | $48 |
| Pfizer | 3 | $37 |
| Verona Pharma, Inc. | 2 | $33 |
| Abiomed | 1 | $33 |
| Baxter Healthcare | 2 | $27 |
| Abbott | 1 | $23 |
| United Therapeutics Corporation | 1 | $23 |
| Novartis | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Resmed Corp | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Insmed, Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$1,355 in reported general payments places this provider in the 70th percentile of 240 acute care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 238 | $239,326 |
| EntrestoSacubitril/Valsartan | 139 | $117,640 |
| XareltoRivaroxaban | 63 | $82,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $70,521 |
| Repatha SureclickEvolocumab | 70 | $37,507 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $26,546 |
| Praluent PenAlirocumab | 26 | $16,547 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $12,421 |
| Repatha SyringeEvolocumab | 15 | $11,392 |
| BrilintaTicagrelor | 24 | $10,722 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,698 |
| Spiriva HandihalerTiotropium Bromide | 14 | $6,677 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,100 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $5,750 |
| DuleraMometasone/Formoterol | 15 | $5,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $37 | $239,326238 claims |
| NovartisEntresto | $20 | $117,640139 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $57 | $115,589159 claims |
| AstraZenecaBrilinta | $20 | $10,72224 claims |
| Boehringer IngelheimStiolto Respimat | $167 | $6,69814 claims |
| MerckDulera | $212 | $5,24315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 240 acute care providers in Indiana.
Other acute care in Vincennes
- Julie HannahVincennes$3K
- Julia McGowanVincennes$2K
- Deanna FieldsVincennes$2K
- Melissa LorenzJeffersonville$19K
- Amara Wright-TerryMunster$17K
- Wen CaiNewburgh$12K
- Erin BarthSouth Bend$10K
- Sarah LongNewburgh$8K
- Aaron HoldermanNewburgh$8K
- Lauren ArmingtonIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.